Duclos Gary, Lakbar Ines, Boucekine Mohamed, Lolo Georges, Cassir Nadim, Leone Marc
Department of Anesthesiology and Intensive Care Unit, Nord Hospital, Assistance Publique Hôpitaux Universitaire de Marseille, Aix Marseille University, Marseille, France.
Service d'anesthésie et de réanimation polyvalente et traumatologique, Hôpital Nord, chemin des Bourrely, 13015, Marseille, France.
Adv Ther. 2023 Apr;40(4):1736-1749. doi: 10.1007/s12325-023-02448-7. Epub 2023 Feb 22.
Multidrug-resistant bacteria (MDRB) carriage may impact the outcomes of intensive care unit (ICU) patients. In this study, we aimed to assess the effect of MDRB-related infection and colonization on the day 60 mortality rate.
We conducted a retrospective, observational study in a single university hospital ICU. From January 2017 to December 2018, we screened all patients admitted to the ICU for at least 48 h for MDRB carriage. The primary outcome was the mortality rate on day 60 after MDRB-related infection. The secondary outcome was the mortality rate on day 60 of non-infected but colonized patients with MDRB. We considered the effect of potential confounders, such as the occurrence of septic shock, inadequate antibiotic therapy, Charlson score, and life-sustaining limitation order.
We included 719 patients during the aforementioned period; of this number, 281 (39%) had a microbiologically documented infection. MDRB was found in 40 (14%) patients. The crude mortality rate in the MDRB-related infection group was 35% vs. 32% in the non-MDRB-related infection group (p = 0.1). Logistic regression showed that MDRB-related infection was not associated with excess mortality, with an odds ratio of 0.52 and a 95% confidence interval from 0.17 to 1.39 (p = 0.2). Charlson score, septic shock, and life-sustaining limitation order were significantly associated with an increased mortality rate on day 60. No effect of MDRB colonization on mortality rate on day 60 was highlighted.
MDRB-related infection or colonization was not associated with an increased mortality rate on day 60. Other confounders, such as comorbidities, may account for a higher mortality rate.
多重耐药菌(MDRB)携带情况可能会影响重症监护病房(ICU)患者的治疗结果。在本研究中,我们旨在评估MDRB相关感染和定植对第60天死亡率的影响。
我们在一所大学医院的ICU进行了一项回顾性观察研究。2017年1月至2018年12月期间,我们对所有入住ICU至少48小时的患者进行了MDRB携带情况筛查。主要结局是MDRB相关感染后第60天的死亡率。次要结局是非感染但MDRB定植患者第60天的死亡率。我们考虑了潜在混杂因素的影响,如感染性休克的发生、抗生素治疗不充分、查尔森评分和维持生命限制令。
在上述期间,我们纳入了719例患者;其中,281例(39%)有微生物学记录的感染。40例(14%)患者检测到MDRB。MDRB相关感染组的粗死亡率为35%,非MDRB相关感染组为32%(p = 0.1)。逻辑回归显示,MDRB相关感染与额外死亡率无关,比值比为0.52,95%置信区间为0.17至1.39(p = 0.2)。查尔森评分、感染性休克和维持生命限制令与第60天死亡率增加显著相关。未发现MDRB定植对第60天死亡率有影响。
MDRB相关感染或定植与第60天死亡率增加无关。其他混杂因素,如合并症,可能导致更高的死亡率。